Rna Based Therapeutics And Vaccines Market : Table of Content


  • Published On : Aug-2018 |
  • Pages : 177 Pages |
  • Format : Rna Based Therapeutics And Vaccines Market Rna Based Therapeutics And Vaccines Market Rna Based Therapeutics And Vaccines Market Rna Based Therapeutics And Vaccines Market

1. Executive Summary
     1.1. Market Overview
     1.2. Market Analysis
     1.3. PMR Analysis and Recommendations

2. Market Introduction
     2.1. Market Definition
     2.2. Market Taxonomy

3. RNA-based Therapeutics and Vaccines Market Opportunity Analysis
     3.1. Macro-Economic Factors
     3.2. Opportunity Analysis

4. Market Background
     4.1. Regulatory Scenario
     4.2. Market Dynamics
            4.2.1. Drivers
            4.2.2. Restraints
            4.2.3. Opportunity Analysis
     4.3. Pipeline Assessment

5. Gross Domestic Product by Region & Country, 2006 – 2021

6. North America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2019–2026
     6.1. Introduction
     6.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2019–2026
            6.2.1. U.S.
            6.2.2. Canada
     6.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2019–2026
            6.3.1. RNA-based Therapeutics
                     6.3.1.1. siRNA
                     6.3.1.2. miRNA
            6.3.2. RNA-based Vaccines
                     6.3.2.1. mRNA
     6.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2019–2026
            6.4.1. Oncology
            6.4.2. Immunology
            6.4.3. Ophthalmology
            6.4.4. Cardiovascular Diseases
            6.4.5. Infectious Diseases
            6.4.6. Genetic Diseases
            6.4.7. Others
     6.5. Drivers and Restraints – Impact Analysis

7. Latin America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2019–2026
     7.1. Introduction
     7.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2019–2026
            7.2.1. RNA-based Therapeutics
                     7.2.1.1. siRNA
                     7.2.1.2. miRNA
            7.2.2. RNA-based Vaccines
                     7.2.2.1. mRNA
     7.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2019–2026
            7.3.1. Oncology
            7.3.2. Immunology
            7.3.3. Ophthalmology
            7.3.4. Cardiovascular Diseases
            7.3.5. Infectious Diseases
            7.3.6. Genetic Diseases
            7.3.7. Others
     7.4. Drivers and Restraints – Impact Analysis

8. Europe RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2019–2026
     8.1. Introduction
     8.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2019–2026
            8.2.1. Germany
            8.2.2. U.K.
            8.2.3. France
            8.2.4. Italy
            8.2.5. Spain
            8.2.6. Russia
            8.2.7. Rest of Europe
     8.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2019–2026
            8.3.1. RNA-based Therapeutics
                     8.3.1.1. siRNA
                     8.3.1.2. miRNA
            8.3.2. RNA-based Vaccines
                     8.3.2.1. mRNA
     8.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2019–2026
            8.4.1. Oncology
            8.4.2. Immunology
            8.4.3. Ophthalmology
            8.4.4. Cardiovascular Diseases
            8.4.5. Infectious Diseases
            8.4.6. Genetic Diseases
            8.4.7. Others
     8.5. Drivers and Restraints – Impact Analysis

9. Asia Pacific RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2019–2026
     9.1. Introduction
     9.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2019–2026
            9.2.1. China
            9.2.2. Japan
            9.2.3. Australia & New Zealand
            9.2.4. Rest of APAC
     9.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2019–2026
            9.3.1. RNA-based Therapeutics
                     9.3.1.1. siRNA
                     9.3.1.2. miRNA
            9.3.2. RNA-based Vaccines
                     9.3.2.1. mRNA
     9.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2019–2026
            9.4.1. Oncology
            9.4.2. Immunology
            9.4.3. Ophthalmology
            9.4.4. Cardiovascular Diseases
            9.4.5. Infectious Diseases
            9.4.6. Genetic Diseases
            9.4.7. Others
     9.5. Drivers and Restraints – Impact Analysis

10. Middle East & Africa RNA-based Therapeutics and Vaccines Opportunity Assessment 2019–2026
     10.1. Introduction
     10.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2019–2026
            10.2.1. RNA-based Therapeutics
                     10.2.1.1. siRNA
                     10.2.1.2. miRNA
            10.2.2. RNA-based Vaccines
                     10.2.2.1. mRNA
     10.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2019–2026
            10.3.1. Oncology
            10.3.2. Immunology
            10.3.3. Ophthalmology
            10.3.4. Cardiovascular Diseases
            10.3.5. Infectious Diseases
            10.3.6. Genetic Diseases
            10.3.7. Others
     10.4. Drivers and Restraints – Impact Analysis

11. Competition Analysis
     11.1. Competition Dashboard

12. Company Profiles
     12.1. Company Deep Dive
            12.1.1. Alnylam Pharmaceuticals, Inc.
            12.1.2. Arbutus Biopharma Corp.
            12.1.3. Arrowhead Pharmaceuticals, Inc.
            12.1.4. BioNTech AG
            12.1.5. CureVac AG
            12.1.6. Dicerna Pharmaceuticals, Inc.
            12.1.7. Regulus Therapeutics, Inc.
            12.1.8. Marina Biotech, Inc.
            12.1.9. miRagen Therapeutics
            12.1.10. Moderna Therapeutics, Inc.
            12.1.11. Quark Pharmaceuticals, Inc.
            12.1.12. Santaris Pharma A/S (A Roche Company)
            12.1.13. Sylentis S.A.

13. Global RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2019–2026, By Region
     13.1. Introduction/Key Findings
     13.2. Market Size (US$ Mn) Opportunity Assessment By Region, 2019–2026
            13.2.1. North America
            13.2.2. Latin America
            13.2.3. Europe
            13.2.4. Asia Pacific Excluding China
            13.2.5. Middle East & Africa
            13.2.6. China
     13.3. Market Attractiveness Analysis By Region

14. Global Product Opportunity Assessment 2019–2026, By Product Type
     14.1. Introduction/Key Findings
     14.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Product Type, 2019–2026
            14.2.1. RNA-based Therapeutics
                     14.2.1.1. siRNA
                     14.2.1.2. miRNA
            14.2.2. RNA-based Vaccines
                     14.2.2.1. mRNA
     14.3. Market Attractiveness Analysis By Product Type

15. Global Product Opportunity Assessment 2019–2026, By Indication Type
     15.1. Introduction/Key Findings
     15.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Indication Type, 2019–2026
            15.2.1. Oncology
            15.2.2. Immunology
            15.2.3. Ophthalmology
            15.2.4. Cardiovascular Diseases
            15.2.5. Infectious Diseases
            15.2.6. Genetic Diseases
            15.2.7. Others
     15.3. Market Attractiveness Analysis By Indication

16. Global Product  Opportunity Assessment 2019–2026
     16.1. Market Opportunity Assessment By All Segment
     16.2. Absolute $ Opportunity

17. Assumption & Acronyms Used

18. Research Methodology


List of Tables

Table 1: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 2: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 3: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Country
Table 4: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Product Type
Table 5: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Indication
Table 6: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Product Type
Table 7: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Indication
Table 8: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Country
Table 9: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Product Type
Table 10: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Indication
Table 11: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Country
Table 12: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Product Type
Table 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Indication
Table 14: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2019–2026, By Product Type
Table 15: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2019–2026, By Indication
Table 16: Competitive Scenario for Hereditary ATTR Amyloidosis (Patisiran (ALN-TTR02))
Table 17: Competitive Scenario for Hemophilia A Fitusiran (ALN-AT3SC) 
Table 18: Competitive Scenario for Hypercholesterolemia (Inclisiran)
Table 19: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2019–2026, By Region
Table 20: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2019–2026, By Product Type
Table 21: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2019–2026, By Indication


List of Figures

Figure 1: Estimated/Actual launching of RNA Therapeutics and Vaccines and their Impact on market
Figure 2: Global RNA based Vaccines Pipeline Assessment: By Development Phase
Figure 3: Global RNA based Vaccines Pipeline Assessment: By Disease Indication
Figure 4: Global RNA based Therapeutics Pipeline Assessment: By Development Phase
Figure 5: Global RNA based Therapeutics Pipeline Assessment: By Disease Indication
Figure 6: North America RNA-based Therapeutics and Vaccines Market Share, By Country (2019)
Figure 7: North America RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2019 & 2026
Figure 8: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2019–2016
Figure 9: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2019–2016
Figure 10: Europe RNA-based Therapeutics and Vaccines Market Share, By Country (2019)
Figure 11: Europe RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2019 & 2026
Figure 12: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2019–2016
Figure 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Share, By Country (2019)
Figure 14: Asia Pacific RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2019 & 2026
Figure 15: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2019–2016
Figure 16: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2019–2016
Figure 17: Global RNA-based Therapeutics and Vaccines Market Share, By Region (2026)
Figure 18: Global RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2019 & 2026, By Region
Figure 19: Global RNA-based Therapeutics and Vaccines Market Share, By Product Type (2026)
Figure 20: Global RNA-based Therapeutics and Vaccines Market Share, By RNA-based Therapeutics segment (2026) 
Figure 21: Global RNA-based Therapeutics and Vaccines Market Share, By Indication (2026)
Figure 22: Global RNA-based Therapeutics and Vaccines Market Value Analysis and Opportunity Assessment, 2019–2026 (US$ Mn)
Figure 23: Global RNA-based Therapeutics and Vaccines Market Absolute $ Opportunity (US$ Mn), 2019–2026

Rna Based Therapeutics And Vaccines Market - Table of Content

Back To Top